Hilgartner M W, Knatterud G L
Blood. 1983 Jan;61(1):36-40.
FEIBA (factor eight inhibitor by-passing activity) Immuno was used to achieve hemostasis in 46 patients with factor VIII inhibitors with titers greater than 4 Bethesda units, and 3 patients with factor IX inhibitors. One-hundred and sixty-five bleeding episodes were treated with 50-70 U/kg; 102 of these episodes occurred in joints. 20 in mucous membranes, 33 muscle and soft tissue, and 10 were emergency episodes including 3 central nervous system and 4 surgical procedures. Ninety-three percent of the bleeding episodes were controlled, while 7% were not controlled: 36% were controlled by one infusion in 12 hr, another 42% with 1 or more infusions in 36 hrs and an additional 14% were controlled in more than 36 hr. There were no serious side effects, and while the inhibitor titer rose in 10 of the patients, the product continued to be efficacious.
FEIBA（凝血因子 VIII 抑制物旁路活性）免疫制品被用于 46 例凝血因子 VIII 抑制物效价高于 4 贝塞斯达单位的患者以及 3 例凝血因子 IX 抑制物患者的止血治疗。165 次出血发作采用 50 - 70 U/kg 进行治疗；其中 102 次发作发生在关节。20 次在黏膜，33 次在肌肉和软组织，10 次为紧急发作，包括 3 次中枢神经系统发作和 4 次外科手术。93%的出血发作得到控制，7%未得到控制：36%在 12 小时内通过一次输注得到控制，另外 42%在 36 小时内通过 1 次或更多次输注得到控制，还有 14%在超过 36 小时后得到控制。未出现严重副作用，虽然 10 例患者的抑制物效价有所上升，但该制品仍继续有效。
